Related Experiment Video
Updated: Oct 9, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma
J A Ajani1, J Fairweather, P W Pisters
1Department of Gastrointestinal Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Abstract:
Chemotherapy for advanced gastric and gastroesophageal junction carcinomas remains suboptimal. Both irinotecan (Camptosar) and cisplatin (Platinol) are active against this group of malignancies. This article focuses on the results of an ongoing phase II trial with this combination in patients with advanced gastric or gastroesophageal junction carcinoma. Data from this trial suggest that the combination of irinotecan and cisplatin is active in untreated as well as previously treated patients with gastric or gastroesophageal junction carcinoma.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
